Charles River Laboratories
560 hedge funds and large institutions have $9.86B invested in Charles River Laboratories in 2026 Q1 according to their latest regulatory filings, with 74 funds opening new positions, 191 increasing their positions, 198 reducing their positions, and 88 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
23% more call options, than puts
Call options by funds: $40.9M | Put options by funds: $33.4M
8.65% more ownership
Funds ownership: 107.45% → 116.1% (+8.6%)
4% less repeat investments, than reductions
Existing positions increased: 191 | Existing positions reduced: 198
4% less funds holding
Funds holding: 583 → 560 (-23)
7% less capital invested
Capital invested by funds: $10.6B → $9.86B (-$692M)
16% less first-time investments, than exits
New positions opened: 74 | Existing positions closed: 88
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$319M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$195M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$147M |
| 4 |
Millennium Management
New York
|
+$112M |
| 5 |
Amundi
Paris,
France
|
+$91.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$63.6M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$55.4M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$51M |
| 4 |
Walleye Capital
New York
|
-$46.2M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$44.2M |
CRL Hedge Fund Activity: Q1 2026 in Review
560 of the 8,208 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q1 2026, worth a combined $9.86B — down 6.6% from $10.6B a quarter earlier.
Sellers outnumbered buyers: 88 funds closed out of CRL and 74 opened new positions — a net loss of 14 holders — while 198 trimmed existing stakes and 191 added.
The largest buyer was Fidelity Investments, adding an estimated $319M. The largest seller was Woodline Partners, cutting an estimated $63.6M.
- 560 institutional investors held Charles River Laboratories (CRL) as of Q1 2026, down from 583 in Q4 2025.
- Funds reported $9.86B of Charles River Laboratories stock for Q1 2026, down 6.6% quarter-over-quarter.
- 74 funds opened new Charles River Laboratories positions in Q1 2026 and 88 closed out, a net change of -14 holders.
- The largest Charles River Laboratories buyer in Q1 2026 was Fidelity Investments, an estimated $319M added.
- The largest Charles River Laboratories seller in Q1 2026 was Woodline Partners, an estimated $63.6M sold.
Based on aggregated 13F filings for Q1 2026.